Additional Relevant Details Enata Pharmaceuticals (a biotech company that focuses on viral infections and liver disease) recently expanded its research and is developing two new programs for Respiratory Syncytial Virus (RSV) and Hepatitis B Virus (HBV).  RSV is a viral lung infection that leads to bronchitis and pneumonia.  HBV is a liver infection that can lead to chronic liver diseases.  The Company expects to initiate Phase 1 trials of at least one of these programs in 2017.